Diabetes guidelines: easier to preach than to practise? A retrospective audit of outpatient management of type 1 and type 2 diabetes mellitus

被引:79
作者
Bryant, Wendy
Greenfield, Jerry R.
Chisholm, Donald J.
Campbell, Lesley V. [1 ]
机构
[1] St Vincents Hosp, Ctr Diabet, Sydney, NSW 2010, Australia
[2] St Vincents Hosp, Dept Endocrinol, Sydney, NSW 2010, Australia
[3] Garvan Inst Med Res, Diabet & Obes Res Program, Sydney, NSW, Australia
关键词
D O I
10.5694/j.1326-5377.2006.tb00583.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To review the management of glycaemia, blood pressure and serum lipids in a hospital outpatient diabetes clinic, the director of which co-authored the current national diabetes management guidelines. Design: Retrospective audit. Setting: Outpatient diabetes clinic in a tertiary referral teaching hospital, Sydney, NSW. Study population: 96 patients with type 1 diabetes (mean age, 44.4 [SD, 12.8] years) and 509 patients with type 2 diabetes (mean age, 64.4 [SD, 12.0] years) attending the clinic in 2003, who had undergone formal review of complications. Main outcome measures: Weight, height, control and treatment of glycaemia, blood pressure and serum lipids, and prevalence of diabetic microvascular complications. Results: Glycated haemoglobin (HbA(1c)) was < 7% in 13% of type 1 and 30% of type 2 diabetes patients, and > 8% in 47% and 34%, respectively. 35% of patients with type 1 diabetes and 71% of patients with type 2 diabetes were treated with anti hypertensive agents. Of these patients, 29% and 24%, respectively, had blood pressure readings <= 130/80 mmHg. Among patients not treated with hypertensive agents, blood pressure readings were <= 130/80 mmHg in 60% of type 1 and 38% of type 2 diabetes patients. About 30% of patients with type 1 diabetes and 50% of those with type 2 diabetes were being treated with lipid-lowering agents; of these, about 60% had low-density lipoprotein (LDL) cholesterol levels < 2.6 mmol/L. Among patients not treated with lipid-lowering agents, about 40% had LDL cholesterol levels < 2.6 mmol/L. Retinopathy was documented in 52% and 18%, and nephropathy in 9% and 36% of type 1 and type 2 diabetes patients, respectively. Conclusions: Despite the demonstrated benefits of tight glucose, blood pressure and lipid control in reducing the risk of macrovascular and microvascular complications in type 1 and type 2 diabetes, our results suggest that treatment targets are not being met in a large proportion of patients attending a tertiary referral hospital. Responsible practice suggests that treatment targets and the current means to achieve them should both be examined.
引用
收藏
页码:305 / 309
页数:5
相关论文
共 39 条
[1]  
American Diabetes Association, 2003, DIABETES CARE S1, V26, pS33, DOI [DOI 10.2337/DIACARE.26.2007.S33, 10.2337/diacare.26.2007.s33]
[2]  
[Anonymous], 2005, DIABETES CARE, V28, pS4
[3]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[4]   Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care suing [J].
Beaton, SJ ;
Nag, SS ;
Gunter, MJ ;
Gleeson, JM ;
Sajjan, SS ;
Alexander, CM .
DIABETES CARE, 2004, 27 (03) :694-698
[5]   Oral agents in type 2 diabetes: where to now? [J].
Campbell, LV ;
Chisholm, DJ .
MEDICAL JOURNAL OF AUSTRALIA, 1999, 171 (02) :64-65
[6]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[7]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[9]  
Collins R, 2003, LANCET, V361, P2005
[10]   Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials [J].
Costa, Joao ;
Borges, Margarida ;
David, Claudio ;
Carneiro, Antnio Vaz .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7550) :1115-1118C